BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 16651448)

  • 1. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
    Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
    Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perforin-deficient CD8+ T cells provide immunity to Listeria monocytogenes by a mechanism that is independent of CD95 and IFN-gamma but requires TNF-alpha.
    White DW; Harty JT
    J Immunol; 1998 Jan; 160(2):898-905. PubMed ID: 9551927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perforin-mediated effector function within the central nervous system requires IFN-gamma-mediated MHC up-regulation.
    Bergmann CC; Parra B; Hinton DR; Chandran R; Morrison M; Stohlman SA
    J Immunol; 2003 Mar; 170(6):3204-13. PubMed ID: 12626579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive immunity and enhanced CD8+ T cell response to Listeria monocytogenes in the absence of perforin and IFN-gamma.
    Badovinac VP; Harty JT
    J Immunol; 2000 Jun; 164(12):6444-52. PubMed ID: 10843700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27.
    Morishima N; Owaki T; Asakawa M; Kamiya S; Mizuguchi J; Yoshimoto T
    J Immunol; 2005 Aug; 175(3):1686-93. PubMed ID: 16034109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
    Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
    Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perforin and gamma interferon-mediated control of coronavirus central nervous system infection by CD8 T cells in the absence of CD4 T cells.
    Bergmann CC; Parra B; Hinton DR; Ramakrishna C; Dowdell KC; Stohlman SA
    J Virol; 2004 Feb; 78(4):1739-50. PubMed ID: 14747539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for CD8+ T-cell immunity to murine rotavirus in the absence of perforin, fas, and gamma interferon.
    Franco MA; Tin C; Rott LS; VanCott JL; McGhee JR; Greenberg HB
    J Virol; 1997 Jan; 71(1):479-86. PubMed ID: 8985374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis.
    Hollenbaugh JA; Reome J; Dobrzanski M; Dutton RW
    J Immunol; 2004 Aug; 173(3):1738-43. PubMed ID: 15265903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.
    Poehlein CH; Hu HM; Yamada J; Assmann I; Alvord WG; Urba WJ; Fox BA
    J Immunol; 2003 Feb; 170(4):2004-13. PubMed ID: 12574370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms.
    Hsieh MH; Patterson AE; Korngold R
    Biol Blood Marrow Transplant; 2000; 6(3):231-40. PubMed ID: 10871148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Hylind JC; Dutton RW
    Cancer Res; 2004 Jan; 64(1):406-14. PubMed ID: 14729652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells.
    Williams NS; Engelhard VH
    J Immunol; 1997 Sep; 159(5):2091-9. PubMed ID: 9278294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.
    Roth E; Pircher H
    J Immunol; 2004 Feb; 172(3):1588-94. PubMed ID: 14734739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.